Drug intelligence / Profile preview

SBC101

Development stage: Preclinical
Lead developer: SapiensBio
Modality: Small Molecules
Administration: Oral

Overview

SBC101 (AI-1944) is an orally bioavailable small molecule inhibitor of the actin-related protein 2/3 complex subunit 2 (ARPC2), currently being developed by SapiensBio for the treatment of idiopathic pulmonary fibrosis (IPF). Identified using the company's AI-driven SAPIENTIA platform, SBC101 directly binds to ARPC2 to inhibit the function of the ARP2/3 complex, which is essential for actin polymerization and cellular processes involved in the progression of fibrosis. Preclinical studies in bleomycin-induced lung fibrosis models have demonstrated therapeutic efficacy and a favorable safety profile. The drug is currently in the IND-enabling stage of development.

Targets

ARPC2 (Actin-related protein 2/3 complex subunit 2)

Beyond the preview

Go deeper on SBC101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBC101.

Explore the full profile